Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 165

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 165
---
 the performance period. Stock OptionsA summary of the stock option activity under the Company's inducement awards for the twelve months ended December 31, 2024 is as follows:(number of shares in millions)NumberofsharesWeightedaverageexercisepriceWeightedaverageremainingcontractuallife (years)Options outstanding at December 31, 20230.7 $13.38 Options outstanding at December 31, 20240.7 13.38 2.62Options exercisable at December 31, 20240.5 13.38 2.62Options vested and expected to vest0.2 $13.38 2.62There were no options granted during the years ended December 31, 2024, 2023, and 2022. 

96

Table of Contents

Restricted Stock UnitsA summary of the RSU awards activity under the Company's equity plans and inducement awards, including PSU awards, for the year ended December 31, 2024 is as follows:(number of shares in millions)NumberofsharesWeightedaveragegrant datefair valueRSUs unvested and outstanding at December 31, 20234.4$24.37 RSUs granted2.7 $22.09 Less:RSUs vested(1.6)$22.98 RSUs canceled(0.2)$23.58 RSUs unvested and outstanding at December 31, 20245.3 $23.66 The weighted average grant-date fair value of RSUs granted during the years ended December 31, 2024, 2023, and 2022, was $22.09, $23.02, and $25.78, respectively.The fair value of RSUs that vested during the years ended December 31, 2024, 2023, and 2022, was $37.9 million, $30.5 million, and $31.0 million, respectively. Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:Years Ended December 31,(in millions)202420232022Cost of revenue$1.6 $1.4 $1.7 Research and development expense8.8 4.0 5.2 Sales and marketing expense9.0 7.2 6.2 General and administrative expense30.4 28.1 25.